Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310-948-2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

freetolife Sep. 16 at 3:35 PM

$KAPA what re u doing now, KOl are all one sided to KAPA, HAHAHA

0 · Reply

freetolife Sep. 16 at 3:29 PM

$KAPA run off here, never long words have the truth we wanna be

0 · Reply

TekuTrader Sep. 16 at 3:21 PM

$KAPA dip got bought up!

0 · Reply

DARKP00L Sep. 16 at 3:17 PM

$KAPA this stock is attracting a lot of interest. Be prepared for possible changes!

1 · Reply

EthiEthiooo Sep. 16 at 3:13 PM

$KAPA Certain Warrants of Kairos Pharma, Ltd. are subject to a Lock-Up Agreement Ending on 16-SEP-2025. These Warrants will be under lockup for 365 days starting from 16-SEP-2024 to 16-SEP-2025. https://www.marketscreener.com/news/certain-warrants-of-kairos-pharma-ltd-are-subject-to-a-lock-up-agreement-ending-on-16-sep-2025-ce7d58dadf80f62d I don't get this? These warrants were to the investment bank that managed their IPO. The price needed to be $4.80 or more for the firm to sell them. Today, they expire worthless. Why plan the call 2 days after these warrants expire. They expire today??

0 · Reply

BagholderGrandpa007 Sep. 16 at 3:11 PM

$KAPA not complaining buying 2500 shares at 1.51 today it’s such a volatile ticker

0 · Reply

j123321 Sep. 16 at 2:58 PM

$KAPA Now Back to Green :)

0 · Reply

Jamjams7 Sep. 16 at 2:56 PM

$KAPA Where are you, Freddy? Are you crying now?? ㅋㅋㅋ

0 · Reply

j123321 Sep. 16 at 2:43 PM

$KAPA Going Strong ... Inflow more than outflow Tomorrow the actual ride will start so buy while it is cheap :)

0 · Reply

Limer_814 Sep. 16 at 2:20 PM

$KAPA weathering the storm

0 · Reply

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 3, 2025, 8:15 AM EDT - 13 days ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 13 days ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 12:28 PM EDT - 7 weeks ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 2 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 15, 2025, 2:08 PM EDT - 2 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 3 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 4 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 7 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 7 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 7 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 7 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 8 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 8 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 9 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 26, 2024, 7:51 AM EST - 9 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 16, 2024, 12:15 PM EST - 9 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 10 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 10 months ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 11 months ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

freetolife Sep. 16 at 3:35 PM

$KAPA what re u doing now, KOl are all one sided to KAPA, HAHAHA

0 · Reply

freetolife Sep. 16 at 3:29 PM

$KAPA run off here, never long words have the truth we wanna be

0 · Reply

TekuTrader Sep. 16 at 3:21 PM

$KAPA dip got bought up!

0 · Reply

DARKP00L Sep. 16 at 3:17 PM

$KAPA this stock is attracting a lot of interest. Be prepared for possible changes!

1 · Reply

EthiEthiooo Sep. 16 at 3:13 PM

0 · Reply

BagholderGrandpa007 Sep. 16 at 3:11 PM

$KAPA not complaining buying 2500 shares at 1.51 today it’s such a volatile ticker

0 · Reply

j123321 Sep. 16 at 2:58 PM

$KAPA Now Back to Green :)

0 · Reply

Jamjams7 Sep. 16 at 2:56 PM

$KAPA Where are you, Freddy? Are you crying now?? ㅋㅋㅋ

0 · Reply

j123321 Sep. 16 at 2:43 PM

$KAPA Going Strong ... Inflow more than outflow Tomorrow the actual ride will start so buy while it is cheap :)

0 · Reply

Limer_814 Sep. 16 at 2:20 PM

$KAPA weathering the storm

0 · Reply

j123321 Sep. 16 at 2:18 PM

$KAPA Most likely SL hunting below $1.50 Thats why it snap back up quickly @ 1.58 now

1 · Reply

Jamjams7 Sep. 16 at 2:17 PM

$KAPA hahaha Freddie sold this around $1.5

0 · Reply

stockforce123 Sep. 16 at 2:14 PM

$KAPA 100% Trust in the CEO. Buying another $20K

0 · Reply

TB85 Sep. 16 at 2:11 PM

$KAPA Nothing leaked, would have tanked more if so, right!? So, whats the reason, so close to results, shorting?

0 · Reply

FreddieMercury91 Sep. 16 at 1:57 PM

$KAPA that golden cross that was promoted here worked well lol. sorry for the people who bought this garbage but I warned you.

0 · Reply

FreddieMercury91 Sep. 16 at 1:45 PM

$KAPA sold what was left. f off KAPA lol.

0 · Reply

EthiEthiooo Sep. 16 at 1:42 PM

$KAPA Warrants expire worthless today as price is not over $4.80. Also, those in pre IPO can now excercise. Someone raised a question here, why phase 2 results 2 days after warrants to the investment bank expire on the 16th of Sep. In that process , the company woud also lose out on the money $3.5M. May be they have already been excericed , after all the number of shares has gone up. The really need a good result to move this up. This is a binary play but i have confidence mainly due to the CEO and the way speaks at the KOL. today and tomorrow many be very volatile.

0 · Reply

FreddieMercury91 Sep. 16 at 1:37 PM

$KAPA falling knife. great company

0 · Reply

jbrown645 Sep. 16 at 1:36 PM

$KAPA Huge Upside Potential. Wow.

0 · Reply

Limer_814 Sep. 16 at 1:34 PM

$KAPA 100k volume nothing being exercised

0 · Reply

Phyrodox Sep. 16 at 1:32 PM

$KAPA another day of cheapies? 😄

0 · Reply

joaneegell Sep. 16 at 1:10 PM

$KAPA WOW really burning up the pre-market. Oh my stars and garters! .02!

0 · Reply

Market Cap	36.51M
Revenue (ttm)	0.00
Net Income (ttm)	-2.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,176,100
Avg Vol	6,215,886
Day's Range	N/A - N/A
Shares Out	20.74M
Stochastic %K	29%
Beta	N/A
Analysts	Strong Sell
Price Target	$8.33